Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome

American Journal of Tropical Medicine and Hygiene

Volumn 87, Issue 6, 2012, Pages 1046-1052

  Engsbro, Anne Line ^a,b   Stensvold, C Rune ^c   Nielsen, Henrik V ^c   Bytzer, Peter ^a,b  

^a KØGE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; TETRACYCLINE;

ADULT; ARTICLE; BLASTOCYSTIS; BLASTOCYSTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIENTAMOEBA; DIENTAMOEBIASIS; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; MALE; NONHUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPROTOZOAL AGENTS; DENMARK; DIENTAMOEBA; DIENTAMOEBIASIS; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; METRONIDAZOLE;

DIENTAMOEBA FRAGILIS;

EID: 84871551947     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0761     Document Type: Article

References (60)

1. Choung RS, Locke GR III, 2011. Epidemiology of IBS. Gastroenterol Clin North Am 40: 1-10.
2. Spiegel BM, 2009. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 11: 265-269.
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC, 2006. Functional bowel disorders. Gastroenterology 130: 1480-1491.
4. El-Serag HB, Olden K, Bjorkman D, 2002. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 16: 1171-1185. (Pubitemid 34680762)
5. Agarwal N, Spiegel BM, 2011. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 40: 11-19.
6. Quigley EM, Bergman F, Bytzer P, Fried M, Hunt M, Hungin AP, 2007. Systematic review on the management of irritable bowel syndrome in the European Union. Eur J Gastroenterol Hepatol 19: S11-S37.
7. Quigley EM, Bytzer P, Jones R, Mearin F, 2006. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis 38: 717-723. (Pubitemid 44362188)
8. Thabane M, Kottachchi DT, Marshall JK, 2007. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 26: 535-544. (Pubitemid 47174284)
9. Ghoshal UC, Ranjan P, 2011. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 26 (Suppl 3): 94-101.
10. Jeffery IB, O'Toole PW, Ohman L, ClaessonMJ, Deane J,Quigley EM, Simren M, 2011. An irritable bowel syndrome subtype defined by species-specific alterations in fecal microbiota. Gut 61: 997-1006.
11. Salonen A, de VosWM, PalvaA, 2010. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 156: 3205-3215.
12. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM, 2011. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141: 1792-1801.
13. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S, 2010. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22: 512-515.
14. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS, 2009. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 1033-1049.
15. Majewski M, McCallum RW, 2007. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 52: 139-142.
16. Pimentel M, Chow EJ, Lin HC, 2003. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412-419. (Pubitemid 36232393)
17. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y, 2006. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557-563. (Pubitemid 46780934)
18. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y, 2006. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 51: 1297-1301. (Pubitemid 44315794)
19. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, 2011. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22-32.
20. Esposito I, de Leone A, Di Gregorio S, Giaquinto S, de Magistris L, Ferrieri A, Riegler G, 2007. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 13: 6016-6021. (Pubitemid 350238268)
21. Menees SB, Maneerattannaporn M, Kim HM, Chey WD, 2012. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107: 28-35.
22. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I, 2006. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326-333. (Pubitemid 43381675)
23. Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D, 2011. A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness. Gut Microbes 2: 3-12.
24. Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J, 2010. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 82: 614-619.
25. Lagace-Wiens PR, VanCaeseele PG, Koschik C, 2006. Dientamoeba fragilis: an emerging role in intestinal disease. CMAJ 175: 468-469. (Pubitemid 44492292)
26. Johnson EH, Windsor JJ, Clark CG, 2004. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 17: 553-570. (Pubitemid 38970682)
27. Stensvold CR, Lewis HC, Hammerum AM, Porsbo LJ, Nielsen SS, Olsen KE, Arendrup MC, Nielsen HV, Molbak K, 2009. Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite. Epidemiol Infect 137: 1655-1663.
28. de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Vinje J, van Duynhoven YT, 2001. Etiology of gastroenteritis in sentinel general practices in the Netherlands. Clin Infect Dis 33: 280-288. (Pubitemid 32664828)
29. Stark D, van Hal S, Marriott D, Ellis J, Harkness J, 2007. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol 37: 11-20. (Pubitemid 44958562)
30. Stark D, Beebe N, Marriott D, Ellis J, Harkness J, 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 43: 2718-2723. (Pubitemid 40827944)
31. Girginkardesler N, Coskun S, Cüneyt Balcioǧlu I, Ertan P, Ok UZ, 2003. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 9: 110-113. (Pubitemid 36527054)
32. Colea A, Silard R, Panaitescu D, Florescu P, Roman N, Capraru T, 1980. Studies on Dientamoeba fragilis in Romania. II. Incidence of Dientamoeba fragilis in healthy persons. Arch Roum Pathol Exp Microbiol 39: 49-53. (Pubitemid 10005057)
33. Borody TJ, Warren EF, Wettstein A, Robertson G, Recabarren P, Fontela A, Herdman K, Surace R, 2002. Eradication of Dientamoeba fragilis can resolve IBS-like symptoms. J Gastroenterol Hepatol 17: A103.
34. Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J, 2006. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 22: 92-96. (Pubitemid 43145869)
35. Yakoob J, Jafri W, Beg MA, Abbas Z, Naz S, Islam M, Khan R, 2010. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 107: 679-684.
36. Jimenez-Gonzalez DE, Martinez-Flores WA, Reyes-Gordillo J, Ramirez-Miranda ME, Arroyo-Escalante S, Romero-Valdovinos M, Stark D, Souza-Saldivar V, Martinez-Hernandez F, Flisser A, Olivo-Diaz A, Maravilla P, 2012. Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. Parasitol Res 110: 1269-1275.
37. Engsbro AL, Bytzer P, 2011. Diagnostic strategies in patients suspected of irritable bowel syndrome. Gut 60 (Suppl 3): A58.
38. Stensvold CR, Arendrup MC, Jespersgaard C, Molbak K, Nielsen HV, 2007. Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study. Diagn Microbiol Infect Dis 59: 303-307. (Pubitemid 350016702)
39. Stensvold CR, Nielsen SD, Badsberg JH, Engberg J, Friis-Moller N, Nielsen SS, Nielsen HV, Friis-Moller A, 2011. The prevalence and clinical significance of intestinal parasites in HIV-infected patients in Denmark. Scand J Infect Dis 43: 129-135.
40. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ, 2007. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 5: 534-540. (Pubitemid 46660780)
41. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D, 2012. In vitro susceptibility testing of Dientamoeba fragilis. Antimicrob Agents Chemother 56: 487-494.
42. Verweij JJ, Mulder B, Poell B, van Middelkoop D, Brienen EA, van Lieshout L, 2007. Real-time PCR for the detection of Dientamoeba fragilis in fecal samples. Mol Cell Probes 21: 400-404. (Pubitemid 47259354)
43. Yang J, Scholten T, 1977. Dientamoeba fragilis: a review with notes on its epidemiology, pathogenicity, mode of transmission, and diagnosis. Am J Trop Med Hyg 26: 16-22. (Pubitemid 8051421)
44. Cuffari C, Oligny L, Seidman EG, 1998. Dientamoeba fragilis masquerading as allergic colitis. J Pediatr Gastroenterol Nutr 26: 16-20. (Pubitemid 28023830)
45. Kurt O, Girginkardesler N, Balcioglu IC, Ozbilgin A, Ok UZ, 2008. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect 14: 601-604. (Pubitemid 351639076)
46. Oxner RB, Paltridge GP, Chapman BA, Cook HB, Sheppard PF, 1987. Dientamoeba fragilis: a bowel pathogen? N Z Med J 100: 64-65. (Pubitemid 17057163)
47. Preiss U, Ockert G, Broemme S, Otto A, 1991. On the clinical importance of Dientamoeba fragilis infections in childhood. J Hyg Epidemiol Microbiol Immunol 35: 27-34.
48. Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ, 2007. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 5: 534-540. (Pubitemid 46660780)
49. Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE, 2009. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology 137: 1944-1953.
50. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D, 2008. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28: 239-249. (Pubitemid 351861967)
51. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA, 2005. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100: 115-123. (Pubitemid 41623278)
52. Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, SilbergDG, 2008.Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am J Gastroenterol 103: 2562-2569.
53. Bosman DK, Benninga MA, van de Berg P, Kooijman GC, van Gool T, 2004. Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children. Ned Tijdschr Geneeskd 148: 575-579. (Pubitemid 38387380)
54. Butler WP, 1996. Dientamoeba fragilis. An unusual intestinal pathogen. Dig Dis Sci 41: 1811-1813. (Pubitemid 26319758)
55. Dardick KR, 1983. Tetracycline treatment of Dientamoeba fragilis. Conn Med 47: 69-70. (Pubitemid 13134390)
56. Millet V, Spencer MJ, Chapin M, Stewart M, Yatabe JA, Brewer T, Garcia LS, 1983. Dientamoeba fragilis, a protozoan parasite in adult members of a semicommunal group. Dig Dis Sci 28: 335-339. (Pubitemid 13112187)
57. Norberg A, Nord CE, Evengard B, 2003. Dientamoeba fragilis - a protozoal infection which may cause severe bowel distress. Clin Microbiol Infect 9: 65-68.
58. Spencer MJ, Garcia LS, Chapin MR, 1979. Dientamoeba fragilis . An intestinal pathogen in children? Am J Dis Child 133: 390-393. (Pubitemid 9212625)
59. Spencer MJ, Chapin MR, Garcia LS, 1982. Dientamoeba fragilis: a gastrointestinal protozoan infection in adults. Am J Gastroenterol 77: 565-569. (Pubitemid 12048084)
60. Vandenberg O, Souayah H, Mouchet F, Dediste A, van Gool T, 2007. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr InfectDis J 26: 88-90. (Pubitemid 46045763)